Press release
New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus
In the study, management decisions were simulated to determine the most likely care plan with or without use of the TissueCypher test for guidance Study data
About this update from Castle Biosciences, Inc.
[{"type":"text","content":"\nIn the study, management decisions were simulated to determine the most likely care plan with or without use of the TissueCypher test for guidance\n\n\nStudy data shows TissueCypher test results significantly improved the likelihood of appropriate management and the consistency of management decisions\n\n\n FRIENDSWOOD, Texas--(BUSINESS WIRE)--\nCastle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new study published in The American Journal of Gastroenterology showing how use of TissueCypher® Barrett’s Esophagus test results can significantly improve management decisions for Barrett’s esophagus (BE) patients with low-grade dysplasia (LGD) to improve health outcomes. The full study is available here.\n\n\n“A significant challenge in the clinical management of Barrett’s esophagus is the inconsistency in diagnoses, and thus patient management, when relying solely on pathology review of biopsied tissue,” said Jacques Bergman, M.D., Ph.D., study author, leading BE expert and Professor of Gastrointestinal Endoscopy at the University of Amsterdam and the Amsterdam University Medical Centers, the Netherlands. “As demonstrated in this study, TissueCypher test results offer a tool that may alleviate this challenge by providing objective and actionable risk-stratification that can improve patient care decisions, including the upstaging of care for high-risk patients and the downstaging of care for patients who are at low-risk for progression to more advanced dysplasia or esophageal cancer.”\n\n\nThe study involved a cohort of 154 real patients with community-based LGD and known progression/non-progression outcomes who were followed prospectively as part of the Surveillance versus Radiofrequency Ablation (SURF) trial. Management decision simulations were performed to determine the most likely care plan with or without use of TissueCypher, where each patient’s specimens were reviewed by 30 pathologists, leading to confirmation of dysplasia or downstaging to non-dysplastic Barrett’s esophagus (NDBE) or indefinite for dysplasia (IND). The study results showed the following:\n\n\n\nUsing TissueCypher test results to guide patient management decisions, in conjunction with the standard of care (SOC), significantly increased the likelihood of patients receiving ap...